Abstract
Background
We aimed to individually evaluate IGB and ESG procedures and compare the efficacy, durability, and safety of these procedures.
Methods
Bibliographic databases were systematically searched for studies investigating the use of IGB and ESG for the treatment of obesity. Studies reporting percent total weight loss (%TWL) or percent excess weight loss (%EWL) with at least 12 months of follow-up were included.
Results
A total of 28 studies were included in the final analysis. Only 1 study directly compared ESG to IGB, 9 studies evaluated ESG alone, while 18 studies evaluated IGB. At 12-month follow-up after ESG, mean %TWL was 17.51 (95% CI 16.44–18.58), and %EWL was 60.51 (95% CI 54.39–66.64). Mean %TWL and %EWL after IGB at 12 months was 10.35 (95% CI 8.38–12.32) and 29.65 (95% CI 25.40–33.91), respectively. Mean %TWL and %EWL after IGB were significantly decreased at 18 or 24 months compared to 6 months indicating weight regain after IGB removal. ESG achieved significantly superior weight loss compared to IGB, the difference in mean %TWL was 7.33 (95% CI 5.22–9.44, p value = 0.0001) at 12 months. Serious adverse events were observed in < 5% for both procedures.
Conclusion
Although ESG and IGB are safe and effective for weight loss, our study suggests that ESG results in more significant and sustained weight loss. Nevertheless, a variety of approaches are essential to care for this underserved population, and there are several factors other than weight loss that should be considered in selecting the ideal therapy for individual patients.
Similar content being viewed by others
References
Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013 23(4):427-436.
Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82:425–438.e5. https://doi.org/10.1016/j.gie.2015.03.1964.
Moura D, Oliveira J, De Moura EGH, et al. Effectiveness of intragastric balloon for obesity: a systematic review and meta-analysis based on randomized control trials. Surg Obes Relat Dis. 2016;12:420–9. https://doi.org/10.1016/j.soard.2015.10.077.
Kotinda APST, de Moura DTH, Ribeiro IB, et al. Efficacy of intragastric balloons for weight loss in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials. Obes Surg. 2020; https://doi.org/10.1007/s11695-020-04558-5.
Kumar N, Lopez-Nava G, Sahdala HNP, et al. Endoscopic sleeve gastroplasty: multicenter weight loss results. Gastroenterology. 2015;
Singh S, Hourneaux de Moura DT, Khan A, et al. Safety and efficacy of endoscopic sleeve gastroplasty worldwide for treatment of obesity: a systematic review and meta-analysis. Surg Obes Relat Dis. 2020; https://doi.org/10.1016/j.soard.2019.11.012.
de Miranda Neto AA, de Moura DTH, Ribeiro IB, et al. Efficacy and safety of endoscopic sleeve gastroplasty at mid term in the management of overweight and obese patients: a systematic review and meta-analysis. Obes Surg. 2020;30:1971–87. https://doi.org/10.1007/s11695-020-04449-9.
Ginsberg GG, Chand B, Cote GA, et al. A pathway to endoscopic bariatric therapies. Gastrointest Endosc. 2011;74:943–53. https://doi.org/10.1016/j.gie.2011.08.053.
Saumoy M, Schneider Y, Zhou XK, et al. A single-operator learning curve analysis for the endoscopic sleeve gastroplasty. Gastrointest Endosc. 2018;87:442–7. https://doi.org/10.1016/j.gie.2017.08.014.
Sartoretto A, Marinos G, Sui Z. Endoscopic sleeve gastroplasty for obesity: improved body composition at 1-year follow-up. Gastrointest Endosc. 2019;89:AB260. https://doi.org/10.1016/j.gie.2019.03.292.
Graus Morales J, Crespo Pérez L, Marques A, et al. Modified endoscopic gastroplasty for the treatment of obesity. Surg Endosc. 2018;32:3936–42. https://doi.org/10.1007/s00464-018-6133-0.
Lopez-Nava G, Galvão MP, Bautista-Castaño I, et al. Endoscopic sleeve gastroplasty for obesity treatment: two years of experience. Arq Bras Cir Dig. 2017;30:18–20. https://doi.org/10.1590/0102-6720201700010006.
Kumar N, Abu Dayyeh BK, Lopez-Nava Breviere G, et al. Endoscopic sutured gastroplasty: procedure evolution from first-in-man cases through current technique. Surg Endosc. 2018;32:2159–64. https://doi.org/10.1007/s00464-017-5869-2.
Bhandari M, Jain S, Mathur W, et al. Endoscopic sleeve gastroplasty is an effective and safe minimally invasive approach for treatment of obesity: first Indian experience. Dig Endosc. 2019:den.13508. https://doi.org/10.1111/den.13508.
Barrichello S, Hourneaux de Moura DT, Hourneaux de Moura EG, et al. Endoscopic sleeve gastroplasty in the management of overweight and obesity: an international multicenter study. Gastrointest Endosc. 2019; https://doi.org/10.1016/j.gie.2019.06.013.
Alqahtani A, Al-Darwish A, Mahmoud AE, et al. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc. 2019;89(6):1132–8. https://doi.org/10.1016/j.gie.2018.12.012.
Abu Dayyeh BK, Acosta A, Camilleri M, et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol. 2017;15(1):37–43.e1. https://doi.org/10.1016/j.cgh.2015.12.030.
Fayad L, Cheskin LJ, Adam A, et al. Endoscopic sleeve gastroplasty versus intragastric balloon insertion: efficacy, durability, and safety. Endoscopy. 2019;51:532–9. https://doi.org/10.1055/a-0852-3441.
Agnihotri A, Xie A, Bartalos C, et al. Real-world safety and efficacy of fluid-filled dual intragastric balloon for weight loss. Clin Gastroenterol Hepatol. 2018;16:1081–1088.e1. https://doi.org/10.1016/j.cgh.2018.02.026.
Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006;16:1135–7. https://doi.org/10.1381/096089206778392365.
Ashrafian H, Monnich M, Braby TS, et al. Intragastric balloon outcomes in super-obesity: a 16-year city center hospital series. Surg Obes Relat Dis. 2018;14:1691–9. https://doi.org/10.1016/j.soard.2018.07.010.
Bozkurt S, Coskun H. The early results of intragastric balloon application of different BMI groups. Eur Surg - Acta Chir Austriaca. 2012;44:383–7. https://doi.org/10.1007/s10353-012-0167-7.
Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes. 2017;41:427–33. https://doi.org/10.1038/ijo.2016.229.
Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19:1084–8. https://doi.org/10.1007/s11695-009-9879-6.
Dargent J, Mion F, Costil V, et al. Multicenter randomized study of obesity treatment with minimally invasive injection of hyaluronic acid versus and combined with intragastric balloon. Obes Surg. 2015;25:1842–7. https://doi.org/10.1007/s11695-015-1648-0.
Dogan UB, Gumurdulu Y, Akin MS, et al. Five percent weight lost in the first month of intragastric balloon treatment may be a predictor for long-term weight maintenance. Obes Surg. 2013;23:892–6. https://doi.org/10.1007/s11695-013-0876-4.
Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg. 2012;22:565–71. https://doi.org/10.1007/s11695-011-0514-y.
Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity. 2013;21:1561–70. https://doi.org/10.1002/oby.20414.
Genco A, Balducci S, Bacci V, et al. Intragastric balloon or diet alone? A retrospective evaluation. Obes Surg. 2008;18:989–92. https://doi.org/10.1007/s11695-007-9383-9.
Genco A, Cipriano M, Materia A, et al. Laparoscopic sleeve gastrectomy versus intragastric balloon: a case-control study. Surg Endosc. 2009;23:1849–53. https://doi.org/10.1007/s00464-008-0285-2.
Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70. https://doi.org/10.1381/0960892054222894.
Al Kahtani K, Khan MQ, Helmy A, et al. Bio-enteric intragastric balloon in obese patients: a retrospective analysis of King Faisal specialist hospital experience. Obes Surg. 2010;20:1219–26. https://doi.org/10.1007/s11695-008-9654-0.
Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. 2012;22:896–903. https://doi.org/10.1007/s11695-012-0607-2.
Mui WLM, Ng EKW, Tsung BYS, et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2010;20:1128–32. https://doi.org/10.1007/s11695-008-9766-6.
Nikolic M, Boban M, Ljubicic N, et al. Morbidly obese are ghrelin and leptin hyporesponders with lesser intragastric balloon treatment efficiency: ghrelin and leptin changes in relation to obesity treatment. Obes Surg. 2011;21:1597–604. https://doi.org/10.1007/s11695-011-0414-1.
Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14:991–8. https://doi.org/10.1381/0960892041719671.
Sartoretto A, Sui Z, Hill C, et al. Endoscopic sleeve gastroplasty (ESG) is a reproducible and effective endoscopic bariatric therapy suitable for widespread clinical adoption: a large, international multicenter study. Obes Surg. 2018;28:1812–21. https://doi.org/10.1007/s11695-018-3135-x.
Neto MG, Moon RC, de Quadros LG, et al. Safety and short-term effectiveness of endoscopic sleeve gastroplasty using overstitch: preliminary report from a multicenter study. Surg Endosc. 2019; https://doi.org/10.1007/s00464-019-07212-z.
Tate CM, Geliebter A. Intragastric balloon treatment for obesity: review of recent studies. Adv Ther. 2017;34:1859–75. https://doi.org/10.1007/s12325-017-0562-3.
Genco A, López-Nava G, Wahlen C, et al. Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience. Obes Surg. 2013;23:515–21. https://doi.org/10.1007/s11695-012-0829-3.
Abu Dayyeh BK, Noar MD, Lavin T, et al. 176 pivotal randomized-controlled trial of the adjustable (SPATZ-3) intragastric balloon system for weight loss. Gastrointest Endosc. 2019;89:AB58–9. https://doi.org/10.1016/j.gie.2019.04.020.
Kumar N, Sullivan S, Thompson CC. The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy. Diabetes, Metab Syndr Obes Targets Ther. 2017; https://doi.org/10.2147/DMSO.S95118.
Shah SL, Hajifathalian K, Mehta A, et al. 1105 – impact of concurrent pharmacotherapy with intragastric balloons in the treatment of obesity. Gastroenterology. 2019;156:S–236. https://doi.org/10.1016/s0016-5085(19)37390-1.
Ball W, Raza SS, Loy J, et al. Effectiveness of intra-gastric balloon as a bridge to definitive surgery in the super obese. Obes Surg. 2019;29:1932–6. https://doi.org/10.1007/s11695-019-03794-8.
Alqahtani AR, Elahmedi M, Alqahtani YA, et al. Laparoscopic sleeve gastrectomy after endoscopic sleeve gastroplasty: technical aspects and short-term outcomes. Obes Surg. 2019;29:3547–52. https://doi.org/10.1007/s11695-019-04024-x.
Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010;71:446–54. https://doi.org/10.1016/j.gie.2009.10.027.
Bazerbachi F, Haffar S, Sawas T, et al. Fluid-filled versus gas-filled intragastric balloons as obesity interventions: a network meta-analysis of randomized trials. Obes Surg. 2018;28:2617–25. https://doi.org/10.1007/s11695-018-3227-7.
Bazerbachi F, Vargas EJ, Abu Dayyeh BK. Endoscopic bariatric therapy. Am J Gastroenterol. 2019; https://doi.org/10.14309/ajg.0000000000000239.
Singh S, Hourneaux de Moura DT, Khan A, et al. Safety and efficacy of endoscopic sleeve gastroplasty worldwide for treatment of obesity: a systematic review and meta-analysis. Surg Obes Relat Dis. 2019; https://doi.org/10.1016/J.SOARD.2019.11.012.
Acknowledgments
The authors acknowledge Anna Crawford (Librarian, West Virginia University Health Sciences Library) for conducting the literature searches.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Shailendra Singh, Diogo Turiani Hourneaux de Moura, Ahmad Khan, Mohammad Bilal, Monica Chowdhry, Michele B. Ryan, Ahmad Najdat Bazarbashi declare that they have no conflict of interest. Christopher C Thompson is a consultant for Apollo Endosurgery, USGI medical, Fractyl, Boston Scientific, Medtronic, Olympus, and GI dynamics.
Ethical Approval Statement
All procedures performed in included studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent Statement
Informed consent does not apply.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
Supplementary 1a
(i) (JPG 535 kb)
Supplementary 1a
(ii) (JPG 577 kb)
Supplementary 1a
(i) (PNG 118 kb)
Supplementary 1b
(ii) (JPG 394 kb)
ESM 1
(JPG 2474 kb)
ESM 2
(DOCX 14 kb)
ESM 3
(DOCX 17 kb)
Rights and permissions
About this article
Cite this article
Singh, S., de Moura, D.T.H., Khan, A. et al. Intragastric Balloon Versus Endoscopic Sleeve Gastroplasty for the Treatment of Obesity: a Systematic Review and Meta-analysis. OBES SURG 30, 3010–3029 (2020). https://doi.org/10.1007/s11695-020-04644-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-020-04644-8